The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials
Open accessAbstract
Purpose: Dermatofibrosarcoma protuberans (DFSP) is a dermal sarcoma typically carrying a translocation between chromosomes 17 and 22 that generates functional platelet-derived growth factor B (PDGFB). Patients and Methods: Two distinct phase II trials of imatinib (400 to 800 mg daily) in patients with locally advanced or metastatic DFSP were conducted and closed prematurely, one in Europe (European Organisation for Research and Treatment of Cancer [EORTC]) with 14-week progression-free rate as the primary end point and the other in North America (Southwest Oncology Group [SWOG]) with confirmed objective response rate as the primary end point. In the EORTC trial, confirmation of PDGFB rearrangement was required, and surgery was undertaken after 14 weeks if feasible. The SWOG study confirmed t(17;22) after enrollment. Results: Sixteen and eight patients were enrolled onto the EORTC and SWOG trials, respectively. Tumor size ranged from 1.2 to 49 cm. DFSP was located on head/neck, trunk, and limb in seven, 11, and six patients, respectively, and was classic, pigmented, and fibrosarcomatous DFSP in 13, one, and nine patients, respectively. Metastases were present in seven patients (lung involvement was present six patients). Eleven patients (4%) had partial response as best response, and four patients had progressive disease as best response. Median time to progression (TTP) was 1.7 years. Imatinib was stopped in 11 patients because of progression, one patient because of toxicity, and two patients after complete resection of disease. Median overall survival (OS) time has not been reached; 1-year OS rate was 87.5%. Conclusion: Imatinib is active in DFSP harboring t(17;22) including fibrosarcomatous DFSP, with objective response rate approaching 50%. Response rates and TTP did not differ between patients taking 400 mg daily versus 400 mg twice a day.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y., Issels, R., van Oosterom, A., Hogendoorn, P. C., Van Glabbeke, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17098-0 · Cited by 1,665
Self-citationBuchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
van Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,264
Self-citationBlanke, C. D., Rankin, C., Demetri, G. D., Ryan, C. W., von Mehren, M., Benjamin, R. S., Raymond, A. K., Bramwell, V. H. C., Baker, L. H., Maki, R. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.4452 · Cited by 1,073
Self-citationWest, R. B., Rubin, B. P., Miller, M. A., Subramanian, S., Kaygusuz, G., Montgomery, K., Zhu, S., Marinelli, R. J., De Luca, A., Downs-Kelly, E., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507321103 · Cited by 560
Self-citationMcArthur, G. A., Demetri, G. D., van Oosterom, A., Heinrich, M. C., Debiec-Rychter, M., Corless, C. L., Nikolova, Z., Dimitrijevic, S., & Fletcher, J. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.088 · Cited by 482
Self-citationRubin, B. P., Schuetze, S. M., Eary, J. F., Norwood, T. H., Mirza, S. K., Conrad, E. U., & Bruckner, J. D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.027 · Cited by 364
Self-citationDermatofibrosarcoma protuberans
Gloster, H. M. (1996) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(96)90597-6 · Cited by 352
Shimizu, A., O'Brien, K. P., Sjöblom, T., et al. (1999) · PubMed · Cited by 289
Sjöblom, T., Shimizu, A., O'Brien, K. P., Pietras, K., Cin, P. D., Buchdunger, E., Dumanski, J. P., Östman, A., & Heldin, C. (2001) · PubMed · Cited by 279
Maki, R. G., Awan, R. A., Dixon, R. H., Jhanwar, S., & Antonescu, C. R. (2002) · International Journal of Cancer · doi:10.1002/ijc.10535 · Cited by 250
Heinrich, M. C., Joensuu, H., Demetri, G. D., Corless, C. L., Apperley, J., Fletcher, J. A., Soulieres, D., Dirnhofer, S., Harlow, A., Town, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4575 · Cited by 213
Self-citationThe Role of Radiation Therapy in the Management of Dermatofibrosarcoma Protuberans
Ballo M.D., M. T., Zagars M.D., G. K., Pisters M.D., P., & Pollack M.D., P. D. (1998) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/s0360-3016(97)00895-x · Cited by 180
Blay, J.-Y., El Sayadi, H., Thiesse, P., Garret, J., & Ray-Coquard, I. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn033 · Cited by 158
Gene Expression Patterns and Gene Copy Number Changes in Dermatofibrosarcoma Protuberans
Linn, S. C., West, R. B., Pollack, J. R., Zhu, S., Hernandez‐Boussard, T., Nielsen, T. O., Rubin, B. P., Patel, R. M., Goldblum, J. R., Siegmund, D., et al. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63593-6 · Cited by 153
Self-citationKérob, D., Porcher, R., VEROLA, O., Dalle, S., Maubec, E., Aubin, F., D'Incan, M., Bodokh, I., Boulinguez, S., Madelaine, I., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3401 · Cited by 145
Pédeutour, F., Simon, M., Minoletti, F., Sozzi, G., Pierotti, M. A., Hecht, F., & Turc‐Carel, C. (1995) · PubMed · Cited by 130
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors
Sandberg, A. A., & Bridge, J. A. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(02)00848-8 · Cited by 130
Greco, A., Fusetti, L., Villa, R., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1202051 · Cited by 116
Simon, M., Navarro, M., Roux, D., & Pouysségur, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204426 · Cited by 109
Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate
Labropoulos, S. V., Fletcher, J. A., Oliveira, A. M., Papadopoulos, S., & Razis, E. D. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200504000-00014 · Cited by 100
Price, V. E., Fletcher, J. A., Zieleńska, M., Cole, W. G., Viero, S., Manson, D. E., Stuart, M., & Pappo, A. S. (2004) · Pediatric Blood & Cancer · doi:10.1002/pbc.20249 · Cited by 86
Molecularly targeted treatment for dermatofibrosarcoma protuberans
McArthur, G. A. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.03.038 · Cited by 77
Value of Cytogenetic Analysis in the Treatment of Dermatofibrosarcoma Protuberans
Kérob, D., Pédeutour, F., Lebœuf, C., VEROLA, O., de Kerviler, É., Servant, J. M., Sarandi, F., Bousquet, G., Madelaine, I., Pruvost‐Balland, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7330 · Cited by 30
Cited by
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Self-citationCasali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy096 · Cited by 1,614
Self-citationJudson, I., Verweij, J., Gelderblom, H., Hartmann, J. T., Schöffski, P., Blay, J.-Y., Kerst, J. M., Sufliarsky, J., Whelan, J., Hohenberger, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70063-4 · Cited by 1,183
Self-citationBone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hogendoorn, P. C. W., Athanasou, N., Bielack, S., De Alava, E., Dei Tos, A. P., Ferrari, S., Gelderblom, H., Grimer, R., Sundby Hall, K., Hassan, B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq223 · Cited by 718
Self-citationThe emerging complexity of gene fusions in cancer
Mertens, F., Johansson, B., Fioretos, T., & Mitelman, F. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3947 · Cited by 682
Metadata
- Authors
- Rutkowski, P., Van Glabbeke, M., Rankin, C. J., Ruka, W., Rubin, B. P., Debiec-Rychter, M., Lazar, A., Gelderblom, H., Sciot, R., Lopez-Terrada, D., Hohenberger, P., van Oosterom, A. T., & Schuetze, S. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-04-01
- Volume
- 28
- Issue
- 10
- Pages
- 1772-1779
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2148064549
- Cited by
- 398
- References
- 27
- FWCI
- 22.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.